Research programme: protein kinase C theta inhibitors - Rigel
Latest Information Update: 16 Jul 2016
At a glance
- Originator Rigel Pharmaceuticals
- Class Small molecules
- Mechanism of Action Protein kinase C theta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Graft-versus-host disease; Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO)